MIMEDX to Present at the Piper Sandler 33rd Annual Healthcare Conference
MiMedx Group, Inc. (Nasdaq: MDXG) announced that Timothy R. Wright, CEO, and Rohit Kashyap, Ph.D., Chief Commercial Officer, will present at the Piper Sandler 33rd Annual Healthcare Conference from November 29 to December 2, 2021. The presentation will be available on-demand starting November 22 at 10:00 AM ET on the Company’s website.
MiMedx specializes in regenerative medicine using amniotic tissue, aiming to address acute and chronic wounds, and has supplied over two million allografts to date.
- None.
- None.
MARIETTA, Ga., Nov. 22, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that Timothy R. Wright, Chief Executive Officer, and Rohit Kashyap, Ph.D., Chief Commercial Officer, will present at the Piper Sandler 33rd Annual Healthcare Conference taking place November 29 to December 2, 2021.
Management’s presentation will be available to view on-demand beginning Monday, November 22 at 10:00 AM ET. The webcast will be available on the Events page of the Investors section of the Company’s website at www.mimedx.com. A replay will be available on the Company’s website following the event.
Institutional investors interested in meeting with management may contact their Piper Sandler representative.
About MIMEDX
MIMEDX is an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental biologics, we have both a base business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.MIMEDX.com.
Contacts:
Investors
Jack Howarth
404-360-5681
jhowarth@mimedx.com
Corporate Communications
Hilary Dixon
404-323-4779
hdixon@mimedx.com
FAQ
When is MiMedx's presentation at the Piper Sandler Conference?
Where can I watch the MiMedx presentation?
Who will represent MiMedx at the conference?
What does MiMedx specialize in?
How many allografts has MiMedx supplied?
